For this reason, Pinometostat (EPZ-5676 commercial name) has been primarily tested to treat relapsed/refractory leukemias bearing rearrangement of the MLL gene, and reached Phase 1 clinical trial (www.clinicaltrials.gov; NCT02141828). The gene discussed is KMT2A; the disease is leukemia.